KVUE 10-K Analysis: Why Kenvue's Earnings Recovery Is 97% Non-Operational
Kenvue reported 41% EPS growth in FY2025 — its best result since separating from Johnson & Johnson. But the metric management actually uses to evaluate the business declined 4.6%. The entire recovery traces to $860 million in non-recurring accounting items: impairment cessation, separation cost winddown, and stock compensation forfeitures. Meanwhile, the company's Skin Health & Beauty segment suffered a 30% two-year profit collapse, three product ingredient categories face simultaneous FDA and litigation scrutiny, and 96% of the company's cash sits overseas — while Kenvue pays out 107.6% of net income in dividends. This is the final independent 10-K of a $15.1 billion consumer health company that has already agreed to be absorbed by Kimberly-Clark for $48.1 billion.